Want to see SANA full AI Analyst Report?
SANA Stock Chart & Stats
$3.52
$3.38(204.85%)
At close: 4:00 PM EST
$3.52
$3.38(204.85%)
Day’s Range― - ―
52-Week Range$2.60 - $6.55
Previous CloseN/A
Volume118.31M
Average Volume (3M)2.43M
Market Cap
$971.24M
Enterprise Value$837.53M
Total Cash (Recent Filing)$101.14M
Total Debt (Recent Filing)$75.33M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Jul 30, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding278,291,600
10 Day Avg. Volume3,390,584
30 Day Avg. Volume2,429,628
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)6.41
Price to Sales (P/S)0.00
P/FCF Ratio-7.12
Enterprise Value/Market Cap0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-350.29
Enterprise Value/Ebitda-4.48
Forecast
1Y Price Target
$9.80Price Target Upside178.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.61
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic Mayo Collaboration & InvestmentThe Mayo Clinic equity purchase is a structural partnership that pairs non-dilutive strategic alignment with financing for specific programs (SC451, stem-cell islet products). This deepens clinical collaboration, adds program expertise and validation, and supports sustained R&D execution over the medium term.
Access To Capital Via Recent Equity OfferingA $69M equity raise materially lengthens operational runway and funds development priorities, demonstrating ongoing market access. For a pre-revenue biotech, the ability to raise meaningful capital is a durable operational asset that enables continued trials and program advancement into 2027.
Governance Continuity And Audit StabilityReelection of directors and ratification of EY reinforce board stability and consistent financial oversight. Stable governance and a continuous external auditor reduce execution and reporting risk, supporting steady strategic decision-making important for long-range clinical program delivery.
Bears Say
No Revenue; Large Ongoing LossesSana remains a pre-revenue biotech bearing large recurring operating losses. Persistent negative profitability means the company must continually fund operations externally; until programs yield revenue or achieve partnering/exit value, intrinsic cash needs and value erosion remain structurally material risks.
Negative Cash Flow And Ongoing BurnOperating and free cash flow remain deeply negative despite improvement versus prior years. Because FCF closely mirrors net losses, Sana's development spend translates into real cash outflows, creating a sustained funding requirement that pressures liquidity and forces reliance on external capital.
Balance-sheet Erosion And Dilution DependenceShareholders' equity has materially declined over several years, shrinking the balance-sheet cushion. While debt is moderate, equity erosion increases sensitivity to future dilution; repeated equity raises to fund R&D reduce shareholder value and limit strategic optionality over the medium term.
Sana Biotechnology News
SANA FAQ
What was Sana Biotechnology’s price range in the past 12 months?
Sana Biotechnology lowest stock price was $2.60 and its highest was $6.55 in the past 12 months.
What is Sana Biotechnology’s market cap?
Sana Biotechnology’s market cap is $971.24M.
When is Sana Biotechnology’s upcoming earnings report date?
Sana Biotechnology’s upcoming earnings report date is Jul 30, 2026 which is in 28 days.
How were Sana Biotechnology’s earnings last quarter?
Sana Biotechnology released its earnings results on May 11, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.162 by -$0.008.
Is Sana Biotechnology overvalued?
According to Wall Street analysts Sana Biotechnology’s price is currently Undervalued.
Does Sana Biotechnology pay dividends?
Sana Biotechnology does not currently pay dividends.
What is Sana Biotechnology’s EPS estimate?
Sana Biotechnology’s EPS estimate is -0.15.
How many shares outstanding does Sana Biotechnology have?
Sana Biotechnology has 278,291,600 shares outstanding.
What happened to Sana Biotechnology’s price movement after its last earnings report?
Sana Biotechnology reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.162. Following the earnings report the stock price went down -8.427%.
Which hedge fund is a major shareholder of Sana Biotechnology?
Currently, no hedge funds are holding shares in SANA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sana Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.80 (178.41% Upside)
$9.80 (178.41% Upside)
Hedge Fund Trend
Increased
By 2.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
37.61%
12-Months-Change
Fundamentals
Return on Equity
-161.87%
Trailing 12-Months
Asset Growth
-16.14%
Trailing 12-Months
Company Description
Sana Biotechnology
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
SANA Stock 12 Month Forecast
Average Price Target
$9.80
▲(178.41% Upside)
Technical Analysis
Geron
―
Editas Medicine
―
Crispr Therapeutics AG
―
Taysha Gene Therapies
―
Prime Medicine, Inc.
―
Ownership Overview
14.60% Insiders
11.74% Mutual Funds
17.21% Other Institutional Investors
46.35% Public Companies and
Individual Investors